About Vericel Corp (NASDAQ:VCEL)
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:VCEL
- CUSIP: N/A
- Web: www.aastrom.com
- Market Cap: $137.86 million
- Outstanding Shares: 32,824,000
- 50 Day Moving Avg: $4.86
- 200 Day Moving Avg: $3.47
- 52 Week Range: $2.00 - $6.30
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.05
- P/E Growth: 0.00
- Annual Revenue: $53.77 million
- Price / Sales: 2.56
- Book Value: $0.43 per share
- Price / Book: 9.77
- EBITDA: ($20,030,000.00)
- Net Margins: -14.09%
- Return on Equity: -64.99%
- Return on Assets: -24.84%
- Debt-to-Equity Ratio: 0.58%
- Current Ratio: 2.55%
- Quick Ratio: 2.31%
- Average Volume: 754,211 shs.
- Beta: 3.17
- Short Ratio: 5.26
Frequently Asked Questions for Vericel Corp (NASDAQ:VCEL)
What is Vericel Corp's stock symbol?
Vericel Corp trades on the NASDAQ under the ticker symbol "VCEL."
How were Vericel Corp's earnings last quarter?
Vericel Corp (NASDAQ:VCEL) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.16. The company had revenue of $16.95 million for the quarter. Vericel Corp had a negative return on equity of 64.99% and a negative net margin of 14.09%. View Vericel Corp's Earnings History.
When will Vericel Corp make its next earnings announcement?
Where is Vericel Corp's stock going? Where will Vericel Corp's stock price be in 2017?
3 equities research analysts have issued 12-month price objectives for Vericel Corp's shares. Their predictions range from $6.00 to $7.00. On average, they anticipate Vericel Corp's share price to reach $6.33 in the next twelve months. View Analyst Ratings for Vericel Corp.
Are investors shorting Vericel Corp?
Vericel Corp saw a decline in short interest during the month of September. As of September 15th, there was short interest totalling 1,182,214 shares, a decline of 23.5% from the August 31st total of 1,545,126 shares. Based on an average trading volume of 453,340 shares, the days-to-cover ratio is currently 2.6 days. Currently, 3.6% of the company's shares are sold short.
Who are some of Vericel Corp's key competitors?
Some companies that are related to Vericel Corp include Strongbridge Biopharma PLC (SBBP), Mirna Therapeutics (SYBX), Mereo BioPharma Group PLC (MPH), Fortress Biotech (FBIO), Kamada (KMDA), Peregrine Pharmaceuticals (PPHM), Kadmon Holdings (KDMN), MediWound (MDWD), KalVista Pharmaceuticals (KALV), Alimera Sciences (ALIM), VIVUS (VVUS), Opiant Pharmaceuticals (OPNT), Chiasma (CHMA), Cardiome Pharma Corporation (CRME), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX) and Onconova Therapeutics (ONTX).
Who are Vericel Corp's key executives?
Vericel Corp's management team includes the folowing people:
- Robert L Zerbe M.D., Independent Chairman of the Board
- Dominick C. Colangelo, President, Chief Executive Officer, Director
- Gerard J. Michel, Chief Financial Officer, Vice President - Corporate Development
- Daniel R. Orlando, Chief Operating Officer, Chief Commercial Officer
- Ross Tubo, Chief Scientific Officer
- David Recker M.D., Chief Medical Officer
- Steven C. Gilman Ph.D., Director
- Heidi Hagen, Director
- Kevin F. McLaughlin, Director
- Paul Kevin Wotton Ph.D., Director
How do I buy Vericel Corp stock?
Shares of Vericel Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vericel Corp's stock price today?
MarketBeat Community Rating for Vericel Corp (NASDAQ VCEL)MarketBeat's community ratings are surveys of what our community members think about Vericel Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Vericel Corp stock can currently be purchased for approximately $4.20.
Earnings History for Vericel Corp (NASDAQ:VCEL)Earnings History by Quarter for Vericel Corp (NASDAQ VCEL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||($0.24)||($0.08)||$16.95 million||View||Listen|
|5/10/2017||Q1 2017||($0.19)||($0.31)||$9.36 million||View||N/A|
|5/10/2016||Q116||($0.25)||($0.08)||$11.60 million||$14.10 million||View||Listen|
|3/14/2016||Q415||($0.15)||($0.28)||$17.36 million||$15.40 million||View||Listen|
|11/13/2015||Q315||($0.21)||($0.26)||$10.50 million||$11.30 million||View||Listen|
|8/12/2015||Q215||($0.13)||($0.16)||$11.31 million||$13.60 million||View||Listen|
|5/14/2015||Q115||($0.14)||($0.27)||$11.10 million||$10.80 million||View||Listen|
|3/23/2015||Q414||($0.47)||($0.17)||$10.70 million||$14.70 million||View||Listen|
|11/13/2014||Q314||($0.66)||($0.52)||$6.73 million||$9.66 million||View||N/A|
|8/14/2014||Q214||($1.59)||($0.94)||$2.50 million||$4.43 million||View||N/A|
|3/13/2014||Q413||($1.34)||($0.97)||$0.02 million||$0.01 million||View||N/A|
Earnings Estimates for Vericel Corp (NASDAQ:VCEL)
Current Year EPS Consensus Estimate: $-0.63 EPS
Next Year EPS Consensus Estimate: $-0.38 EPS
Dividend History for Vericel Corp (NASDAQ:VCEL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vericel Corp (NASDAQ:VCEL)
Insider Ownership Percentage: 3.30%Insider Trades by Quarter for Vericel Corp (NASDAQ:VCEL)
Institutional Ownership Percentage: 33.84%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/28/2016||Consonance Capital Management||Major Shareholder||Sell||120,000||$5.39||$646,800.00|| |
|9/16/2014||Daniel Orlando||COO||Buy||9,804||$2.55||$25,000.20|| |
|9/16/2014||Dominick Colangelo||CEO||Buy||20,000||$2.55||$51,000.00|| |
Headline Trends for Vericel Corp (NASDAQ:VCEL)
Latest Headlines for Vericel Corp (NASDAQ:VCEL)
Loading headlines, please wait.
Vericel Corp (VCEL) Chart for Sunday, October, 22, 2017